Mouna Hadiji

Mouna Hadiji

Auto-generated profile, based on publicly available information

Mouna Hadiji

Institute of Chemical Sciences and Engineering (ISIC), Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2022 in Dalton Transactions
Verified
Journal Article
Open access
PDF file
NPNoemi Pagliaricci
Noemi Pagliaricci
RPRiccardo Pettinari
Riccardo Pettinari
Fabio MarchettiFabio Marchetti
Fabio Marchetti
Claudio PettinariClaudio Pettinari
Claudio Pettinari
Loredana CappellacciLoredana Cappellacci
Loredana Cappellacci
PDPaul Dyson
Paul Dyson
Synthesis of Ru (ii) and Os(ii) Arene complexes with curcumin-based ligands. Antitumor activity in vitro against A2780 and A2780cis human ovarian carcinoma cell lines. Structure-activity relationships organometallic anticancer complexes.

21 May 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
SZSoumaila Zebret
Soumaila Zebret
MHMouna Hadiji
Mouna Hadiji
JRJan Romano-Degea
Jan Romano-Degea
ABAurélien Bornet
Aurélien Bornet
DODaniel Ortiz
Daniel Ortiz
PDPaul Dyson
Paul Dyson
Of the different modalities used to treat retinoblastoma, a chemothermotherapeutic regimen combining carboplatin and thermotherapy (also termed focal therapy), and the application of melphalan as a monotherapy, are particularly successful. Some studies indicate that melphalan shows potential when applied in combination with focal therapy, and yet is not applied in this combination. Here we describe a series of synthetically modified melphalan derivatives that display enhanced cytotoxicity relative to melphalan itself, with some displaying further enhancements in cytotoxicity when applied in combination with heat (used as a model for thermotherapy). The synthetic approach, which involves modifying melphalan with perfluorous chains of varying lengths via an ester linker, could lead to a more effective treatment option for retinoblastoma with reduced side-effects, which is a key limitation of melphalan.